Friday 13^th January 2012

14:00      Welcome and introduction (R. Stahel, Zürich)

State of the art, NSCLC cancer therapy 2012

14:05      First line, extended first line, maintenance, second line, a controversial choice (D. Betticher, Fribourg)

14:25      Discussion

14:35      Targeted approaches, state of the art 2012 (S. Peters, Lausanne)

14:55      Discussion

Chemotherapy, radiotherapy, targeted therapy surgery, the art to combine! (W. Weder, Zürich)

15:05      Modern technique of radiotherapy in resectable NSCLC, an alternative approach to surgery? (O. Matzinger, Lausanne)

15:25      Discussion

15:35      Integration of targeted agents in combination with radiotherapy for NSCLC (D. de Ruysscher, Maastricht)

15:55      Discussion

16:05      Coffee break

16:30      Surgery for stage III disease, how to select candidate patients and close the debate? (G. Stamatis, Essen)

16:55      Discussion

Workshop session

17:05      Case presentation (locally advanced NSCLC) (S. Peters / D. Betticher)

17:15      Discussion and preparation of a therapy plan in small groups (4 groups)

17:35      Presentation of therapy plan and discussion (Round table: G. Stamatis, W. Weder, D. de Ruyscher, O. Matzinger, S. Peters, D. Betticher)

18:30      Adjourn

Saturday 14^th January 2012

Pathology results integrated into therapy (M. Pless, Winterthur)

08:00      Increasing knowledge about NSCLC pathways and impact on therapeutic perspective (O. Gautschi, Luzern)

08:20      Discussion

08:30      Role of circulating tumour cells in lung cancer (F. Blackhall, Manchester)

08:50      Discussion

09:00      How to integrate and prioritize the increasing number of biomarkers in NSCLC diagnosis (L. Bubendorf, Basel)

09:20      Discussion

09:30      Finally some good news about squamous cell carcinoma molecular pathology? (A. Soltermann, Zürich)

09:50      Discussion

10:00      Coffee break

Clinical studies: NSCLC / Mesothelioma (O. Gautschi, Luzern)

10:30      Surgical therapy of mesothelioma, who should be operated (W. Weder, Zürich)

10:50      Discussion

11:00      Update on mesothelioma therapy, state of the art 2012 (R. Stahel, Zürich)

11:20      Discussion

11:30      Is overall survival the golden standard endpoint in future clinical studies in NSCLC? (M. Pless, Winterthur)

11:50      Discussion

12:00      Break

Future developments in NSCLC (S. Peters, Lausanne)

12:30      New perspectives and future tools for better screening and evaluation of lung cancer (F. Blackhall, Manchester)

12:50      Discussion

13:00      Adaptive radiotherapy for lung cancer (D. de Ruysscher, Maastricht)

13:20      Discussion

13:30      Mediastinal lymphadenectomy, still the standard? (G. Stamatis, Essen)

13:50      Discussion

14:00      Wrap-up and conclusions (S. Peters, Lausanne)